BR112014028566A2 - composição farmacêutica compreendendo ( 1r , 4r ) - 6 - fluoro n , n - dimetill - 4 - fenil - 4 , 9 - di - hidro - 3h espiro ( ciclohexano 1-1 - pirano ( 3,4,b) indo ) - 4 - amina e um nsar. - Google Patents

composição farmacêutica compreendendo ( 1r , 4r ) - 6 - fluoro n , n - dimetill - 4 - fenil - 4 , 9 - di - hidro - 3h espiro ( ciclohexano 1-1 - pirano ( 3,4,b) indo ) - 4 - amina e um nsar.

Info

Publication number
BR112014028566A2
BR112014028566A2 BR112014028566A BR112014028566A BR112014028566A2 BR 112014028566 A2 BR112014028566 A2 BR 112014028566A2 BR 112014028566 A BR112014028566 A BR 112014028566A BR 112014028566 A BR112014028566 A BR 112014028566A BR 112014028566 A2 BR112014028566 A2 BR 112014028566A2
Authority
BR
Brazil
Prior art keywords
nsar
indo
pyran
spiro
dihydro
Prior art date
Application number
BR112014028566A
Other languages
English (en)
Portuguese (pt)
Inventor
Stefanie Frosch
Klaus Linz
Klaus Schiene
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of BR112014028566A2 publication Critical patent/BR112014028566A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112014028566A 2012-05-18 2013-05-16 composição farmacêutica compreendendo ( 1r , 4r ) - 6 - fluoro n , n - dimetill - 4 - fenil - 4 , 9 - di - hidro - 3h espiro ( ciclohexano 1-1 - pirano ( 3,4,b) indo ) - 4 - amina e um nsar. BR112014028566A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12003895 2012-05-18
PCT/EP2013/001470 WO2013170971A1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and a nsar

Publications (1)

Publication Number Publication Date
BR112014028566A2 true BR112014028566A2 (pt) 2017-06-27

Family

ID=48520892

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014028566A BR112014028566A2 (pt) 2012-05-18 2013-05-16 composição farmacêutica compreendendo ( 1r , 4r ) - 6 - fluoro n , n - dimetill - 4 - fenil - 4 , 9 - di - hidro - 3h espiro ( ciclohexano 1-1 - pirano ( 3,4,b) indo ) - 4 - amina e um nsar.

Country Status (22)

Country Link
US (1) US8912226B2 (enExample)
EP (1) EP2849747B1 (enExample)
JP (1) JP6116678B2 (enExample)
CN (1) CN104284660A (enExample)
AU (1) AU2013262077B2 (enExample)
BR (1) BR112014028566A2 (enExample)
CA (1) CA2873867A1 (enExample)
CY (1) CY1119781T1 (enExample)
DK (1) DK2849747T3 (enExample)
EA (1) EA027145B1 (enExample)
ES (1) ES2658217T3 (enExample)
HR (1) HRP20171725T1 (enExample)
HU (1) HUE034658T2 (enExample)
IL (1) IL235653B (enExample)
LT (1) LT2849747T (enExample)
MX (1) MX356493B (enExample)
NO (1) NO2849747T3 (enExample)
PL (1) PL2849747T3 (enExample)
PT (1) PT2849747T (enExample)
RS (1) RS56788B1 (enExample)
SI (1) SI2849747T1 (enExample)
WO (1) WO2013170971A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022353B2 (en) 2015-01-23 2018-07-17 Grünenthal GmbH Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
WO2017148595A1 (en) 2016-02-29 2017-09-08 Grünenthal GmbH Titration of cebranopadol

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS584720A (ja) 1981-06-26 1983-01-11 ザ・アツプジヨン・カンパニ− 鎮痛用医薬組成物
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4404208A (en) * 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and tiflamizole
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
ES2098264T3 (es) 1989-05-22 1997-05-01 Biochemical Veterinary Res Sales metalicas divalentes de indometacina.
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5914129A (en) 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
EP1219304B1 (de) 2000-12-28 2004-10-20 Fresenius Kabi Austria GmbH Stabile Infusionslösung von Diclofenac-Salzen, deren Herstellung und Verwendung
SI1374906T1 (sl) 2002-06-17 2007-10-31 Chiesi Farma Spa Postopek za pripravo inkluzijskih spojin piroksakama: beta-ciklodekstrina
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10257824B4 (de) 2002-12-10 2004-11-11 Kochem, Hans-Günter, Dr. Zusammensetzung zur Schmerzbehandlung, insbesondere zur Behandlung von Gelenkschmerzen
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US7132452B2 (en) 2003-03-10 2006-11-07 Fang-Yu Lee Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
AU2006257274A1 (en) * 2005-06-17 2006-12-21 Pfizer Inc. Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as ORL1-receptor antagonists
SI2012763T1 (sl) * 2006-04-28 2011-06-30 Gruenenthal Gmbh Farmacevtska kombinacija, ki obsega 3-(3-dimetilamino-1-etil-2-metil- propil)-fenol in NSAID
CN101147735A (zh) 2006-09-19 2008-03-26 沈阳华泰药物研究有限公司 注射用药物组合物及其药盒
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
DE102006056458A1 (de) 2006-11-28 2008-05-29 Grünenthal GmbH Arzneimittelzubereitung von Tramadol und Acetaminophen
AU2008310114B2 (en) * 2007-10-09 2014-01-16 Merck Patent Gmbh Pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
CN100560061C (zh) 2008-06-20 2009-11-18 海南锦瑞制药股份有限公司 一种氯诺昔康冻干粉针剂及其制备方法
MX2011002117A (es) * 2008-09-05 2011-03-28 Gruenenthal Gmbh Combinacion farmaceutica que comprenden 6-dimetilaminometil-1-(3-m etoxi-fenil)-ciclohexano-1,3-diol y un aines.
SI2331210T1 (sl) * 2008-09-05 2014-10-30 Gruenenthal Gmbh Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika
PL2600838T3 (pl) * 2010-08-04 2016-02-29 Gruenenthal Gmbh Farmaceutyczna postać dawkowania zawierająca 6'-fluoro-(N-metylo- lub N,N-dimetylo)-4-fenylo-4'9'-dihydro-3'H-spiro[cykloheksano-1,1'-pirano[3,4b]indolo]-4-aminę
EP2600850B1 (en) * 2010-08-04 2018-10-17 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
JP6010534B2 (ja) * 2010-08-04 2016-10-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ６’−フルオロ−（Ｎ−メチル−又はＮ，Ｎ−ジメチル−）−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンを含む医薬剤形

Also Published As

Publication number Publication date
NO2849747T3 (enExample) 2018-03-31
AU2013262077B2 (en) 2017-10-26
US20130317075A1 (en) 2013-11-28
RS56788B1 (sr) 2018-04-30
HUE034658T2 (hu) 2018-02-28
JP2015516451A (ja) 2015-06-11
WO2013170971A1 (en) 2013-11-21
SI2849747T1 (en) 2018-04-30
IL235653B (en) 2018-08-30
HK1204938A1 (en) 2015-12-11
CA2873867A1 (en) 2013-11-21
HRP20171725T1 (hr) 2017-12-29
EP2849747A1 (en) 2015-03-25
EA027145B1 (ru) 2017-06-30
US8912226B2 (en) 2014-12-16
CN104284660A (zh) 2015-01-14
EA201401270A1 (ru) 2016-05-31
LT2849747T (lt) 2018-01-25
DK2849747T3 (en) 2017-12-04
MX2014013028A (es) 2015-02-04
CY1119781T1 (el) 2018-06-27
JP6116678B2 (ja) 2017-04-19
AU2013262077A1 (en) 2015-01-22
MX356493B (es) 2018-05-31
EP2849747B1 (en) 2017-11-01
PT2849747T (pt) 2018-02-07
PL2849747T3 (pl) 2018-03-30
ES2658217T3 (es) 2018-03-08
IL235653A0 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
BR112014001274A2 (pt) composto de hormônio luteinizante, e, composição farmacêutica
DK3181122T3 (da) Farmaceutisk dasatinib-sammensætning
BR112014029403A2 (pt) conjugados, anticorpo e formulação farmacêutica
EP3016653A4 (en) Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
BR112014025041B8 (pt) Composição farmacêutica
CL2014002019A1 (es) Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.
CL2014003429A1 (es) Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
DK2486051T3 (da) Farmaceutisk præparat, der omfatter rekombinant hcg
CL2014003283A1 (es) Formulación farmacéutica.
BR112015010797A2 (pt) compostos aniônicos substituídos, e, composição farmacêutica
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
BR112014020008A8 (pt) composição farmacêutica, uso da mesma, e, processo para a fabricação de uma formulação.
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
BR112014032501A2 (pt) composto, e, composição farmacêutica.
IL233055A0 (en) (1r,r4) 7-oxo-2-azabicyclo [2.2.2] oct-5-ene and its derivatives
PT2849745T (pt) Composição farmacêutica compreendendo (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-di-hidro-3'h-espiro[ciclo-hexano-1,1'-pirano[3,4,b]indol]-4-amina e ibuprofeno
BR112015006692A2 (pt) formulação de nanodispersão, método para administrar uma formulação de nanodispersão líquida de taxina livre de etanol em um indivíduo, e, kit.
BR112014008588A2 (pt) derivados de 2-oxo-piperidinila
BR112014028566A2 (pt) composição farmacêutica compreendendo ( 1r , 4r ) - 6 - fluoro n , n - dimetill - 4 - fenil - 4 , 9 - di - hidro - 3h espiro ( ciclohexano 1-1 - pirano ( 3,4,b) indo ) - 4 - amina e um nsar.
HRP20180793T1 (hr) Farmaceutski pripravak i oblik doziranja koji sadrži dronedaron, te postupak njegove priprave
BR112014028574A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n , n-dimetil-4 ,9-di-hidro-3h-espiro[ciclo-hexano-1 ,1-pirano-[3,4,b]indol]-4-amina e um gabapentinoide

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time